We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock
SRRA

Delisted

SRRA was delisted on the 30th of June, 2022.

Back to rankings

1 hedge funds and large institutions have $4K invested in Sierra Oncology, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 108 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 109 → 1 (-108)

100% less funds holding in top 10

Funds holding in top 10: 7 → 0 (-7)

100% less capital invested

Capital invested by funds: $1.06B → $4K (-$1.06B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 108

Holders
1
Holders Change
-108
Holders Change %
-99.08%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
108
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$183M
2
VI
Versor Investments
New York
-$86.9M
3
A
Abingworth
United Kingdom
-$72.3M
4
RSCM
Rock Springs Capital Management
Maryland
-$64.6M
5
BlackRock
BlackRock
New York
-$64.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
PMAM
51
Penn Mutual Asset Management
Pennsylvania
– -$2.06M -37,424 Closed
CS
52
Candriam SCA
Luxembourg
– -$2.02M -36,683 Closed
UOC
53
UBS O'Connor
Illinois
– -$1.85M -33,735 Closed
Charles Schwab
54
Charles Schwab
California
– -$1.81M -32,828 Closed
Verition Fund Management
55
Verition Fund Management
Connecticut
– -$1.8M -32,662 Closed
SC
56
Sagefield Capital
Texas
– -$1.68M -30,500 Closed
CS
57
Credit Suisse
Switzerland
– -$1.47M -26,755 Closed
FM
58
Frazier Management
Washington
– -$1.12M -20,316 Closed
CSS
59
Cubist Systematic Strategies
Connecticut
– -$1.11M -20,123 Closed
WIC
60
Water Island Capital
New York
– -$1.08M -19,613 Closed
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
– -$1.05M -19,058 Closed
WMSA
62
Weiss Multi-Strategy Advisers
New York
– -$1.02M -18,648 Closed
BCM
63
BCK Capital Management
Connecticut
– -$1.02M -18,500 Closed
GC
64
Guggenheim Capital
Illinois
– -$1.01M -18,354 Closed
PC
65
Paulson & Co
New York
– -$972K -17,675 Closed
GH
66
GAM Holding
Switzerland
– -$940K -17,100 Closed
NYLIM
67
New York Life Investment Management
New York
– -$918K -16,702 Closed
California State Teachers Retirement System (CalSTRS)
68
California State Teachers Retirement System (CalSTRS)
California
– -$906K -16,467 Closed
HA
69
Havens Advisors
New York
– -$789K -14,350 Closed
TMAM
70
Tokio Marine Asset Management
Japan
– -$786K -14,286 Closed
Skandinaviska Enskilda Banken (SEB)
71
Skandinaviska Enskilda Banken (SEB)
Sweden
– -$753K -13,685 Closed
EA
72
Ellsworth Advisors
Ohio
– -$738K -13,427 Closed
Squarepoint
73
Squarepoint
New York
– -$586K -10,656 Closed
UBS AM
74
UBS AM
Illinois
– -$573K -10,414 Closed
New York State Common Retirement Fund
75
New York State Common Retirement Fund
New York
– -$566K -10,300 Closed
1 2
3
4 5

SRRA Hedge Fund Activity: Q3 2022 in Review

1 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2022, worth a combined $4K — down 100% from $1.06B a quarter earlier.

Sellers outnumbered buyers: 108 funds closed out of SRRA and 0 opened new positions — a net loss of 108 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vivo Capital, exiting entirely with an estimated $183M sold.

  • 1 institutional investor held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2022, down from 109 in Q2 2022.
  • Funds reported $4K of Sierra Oncology, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2022 and 108 closed out, a net change of -108 holders.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q3 2022 was Vivo Capital, an estimated $183M sold.

Based on aggregated 13F filings for Q3 2022.